서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Subject

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 20 of 20

Issue DateTitle / Author(s) / CitationFileAltmetrics
2008-04
Resveratrol induces the suppression of tumor-driven CD4(+) CD25(+) regulatory T cells

Yang, Yoolhee; Paik, Jin Ho; Cho, Daeho; Cho, Jung-Ah; Kim, Chul-Woo

International Immunopharmacology, Vol.8 No.4, pp.542-547

DOI
2011-08
Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles
DOI
2012-03
Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients
DOI
2016-04
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
DOI
2016-05
Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T-cell infiltration
DOI
2017-04
Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy
DOI
2017-08
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
DOI
2017-11
PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study
DOI
2018-05
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives
DOI
2019
Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma
DOI
2019-04
Dynamics of soluble programmed death-ligand 1 (SPDL1) during chemotherapy and its prognostic implications in cancer patients: Biomarker development in immuno-oncology

Ha, Hyerim; Bang, Ju-Hee; Nam, Ah-Rong; Park, Ji-Eun; Jin, Mei Hua; Bang, Yung-Jue; Oh, Do-Youn

Cancer Research and Treatment, Vol.51 No.2, pp.832-840

DOI
2019-07
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
DOI
2020-03
Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies
DOI
2020-06
Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer
DOI
2020-10
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
DOI
2021-03
Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer
DOI
2021-04
Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
DOI
2021-06
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
DOI
2023-11
The prognostic value of a combined immune score in tumor and immune cells assessed by immunohistochemistry in triple-negative breast cancer
DOI
2024-04
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
DOI
1